Abstract: Provided are a rapid in-situ stratified collection device and method for sediment pollution in rivers and lakes. The device includes a main control system, a main collection system, a fixing frame, a bathymetric module, a working hull, and a crane. The bathymetric module is installed below the working hull, the main control system and the crane are both installed on the working hull, the main collection system is fixed in the fixing frame and connected to the crane. The bathymetric module is used to detect and determine a water depth, and thicknesses of sediment. The main control system is used to control a collection process of the main collection system, read the water depth and a thickness of the sediment in real time, and determine whether the main collection system is completely inserted into the sediment. The main collection system is used for stratified collection of sediment pore solution.

Abstract: The present application relates to isolated novel CRISPR/Cas13 proteins, a gene editing systems based thereon, and a method for using said proteins for RNA level gene editing. Provided are non-naturally occurring or engineered RNA targeting systems, and said systems each have a novel Cas13 effector protein that targets RNA and at least one type of guide molecule.

Abstract: The present disclosure provides an in-situ electric stratified remediation device and method for accurate position in remediation depth in sediment. the device includes a telescopic rod, a porous cylinder, a water storage tank, a curing agent storage device, and a depth determining module. The water storage tank is configured to collect sediment pore water and contaminants converged along a surface groove of a columnar electrode; and the fixed determining module is configured to send an indication information in response to that the curing agent storage device is inserted below a mud-water interface, while triggering release of curing agent from a wall of the curing agent shroud.

Abstract: Provided is an engineered Cas12i nuclease, which comprises one or more of the following mutations based on a reference Cas12i nuclease: (1) replacing one or more amino acids interacting with PAM in the reference Cas12i nuclease with positively charged amino acids; and/or (2) replacing one or more amino acids involved in opening the double strands of DNA, in the reference Cas12i nuclease with amino acids with aromatic rings; and/or (3) replacing one or more amino acids, which interact with a single-stranded DNA substrate and are located in an RuvC domain in the reference Cas12i nuclease, with positively charged amino acids; and/or (4) replacing one or more amino acids interacting with a DNA-RNA double helix in the reference Cas12i nuclease with positively charged amino acids; and/or (5) replacing one or more polar or positively charged amino acids interacting with the DNA-RNA double helix in the reference Cas12i nuclease with hydrophobic amino acids.

Abstract: The invention relates to methods and compositions for treating a subject afflicted with a hematological malignancy using a combination of a CXCR4 antagonist and an immunotherapeutic agent.